Rubicon Research Limited
Rubicon Research Limited operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹534 cr of revenue in its latest quarter (Q1 FY27) and kept 15.9% of sales as profit.
Healthier than 56% of companies in Healthcare, on the 5 of 6 measures we could read for it. Each measure is ranked against the 116–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 53
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.
What if I invest in RUBICON?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹534 cr |
| Other Income | ₹6 cr |
| Total Income | ₹540 cr |
| Cost of Materials | ₹154 cr |
| Purchases of Stock-in-Trade | ₹22 cr |
| Inventory Change (±) | ₹-7 cr |
| Employee Benefit Expense | ₹86 cr |
| Finance Costs | ₹9 cr |
| Depreciation & Amortisation | ₹15 cr |
| Other Expenses | ₹151 cr |
| Total Expenses | ₹430 cr |
| Profit before Tax | ₹110 cr |
| Tax Expense | ₹26 cr |
| Net Profit | ₹85 cr |
| Net margin on total income | 15.7% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 476 cr | 514 cr | 534 cr |
| Total income | 479 cr | 517 cr | 540 cr |
| Expenses | 389 cr | 418 cr | 430 cr |
| Profit before tax | 91 cr | 99 cr | 110 cr |
| Tax | 18 cr | 22 cr | 26 cr |
| Net profit (owners' share) | 73 cr | 77 cr | 85 cr |
| Net margin (owners' share, on revenue) | 15.3% | 14.9% | 15.9% |
| EPS (₹) | 4.46 | 4.66 | 5.13 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,867 | ₹4.48 L cr | 38.6 | 13.9% | 18.9% | — |
| Divi's Laboratories Limited | ₹9,323 | ₹2.47 L cr | 68.7 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,875 | ₹1.65 L cr | 82.0 | 27.0% | 11.5% | — |
| Zydus Lifesciences Limited | ₹1,135 | ₹1.13 L cr | 30.4 | 13.9% | 11.7% | — |
| Cipla Limited | ₹1,376 | ₹1.11 L cr | 35.2 | 9.2% | 11.1% | — |
| Laurus Labs Limited | ₹1,948 | ₹1.05 L cr | 71.5 | 27.7% | 18.1% | — |
| Dr. Reddy's Laboratories Limited | ₹1,175 | ₹98,113 cr | 55.1 | 4.7% | 5.5% | — |
| Aurobindo Pharma Limited | ₹1,690 | ₹97,243 cr | 23.7 | 10.9% | 11.3% | — |
| Lupin Limited | ₹2,098 | ₹95,936 cr | 16.9 | 25.2% | 17.1% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹1.5 / share | 7 Aug 2026 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.
When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.
As of Mar 2026, the company says it has spent 69% of what it set aside, leaving ₹148 cr still to be spent. India Ratings & Research Private Limited watches the spending on the exchange’s behalf.
“As disclosed in the Offer Document dated October 13, 2025, the Company had proposed to utilise INR 4,712.74 Million from the IPO net proceeds for identified objects by Fiscal Year 2026. As of March 31, 2026, a total amount of INR 3,236.46 Million has been utilised toward the said objects, whereby the remaining unutilised balance stands at INR 1,476.28 Million.”the company’s own explanation, as filed
The company has not broken this money down into purposes in its filing for Dec 2025, so there is nothing to measure it against yet. India Ratings & Research Private Limited watches the spending on the exchange’s behalf.
Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing